Immunisation is one of the most effective means we have of protecting children against infection. Preterm infants are a vulnerable group and very preterm infants with long term respiratory problems are particularly at risk from respiratory infections such as pertussis; it is therefore important to protect them from pertussis as early as possible. In the United Kingdom the Department of Health recommends that immunisation programmes start at 3 months of age, and the current guidelines also advise starting immunisation of preterm infants at that age. 1 The practice varies across the country with some authorities starting at three months after the actual delivery date, some at three months from expected date of delivery, and some taking an arbitrary figure in between.2 In the United States, it is recommended that preterm infants begin their immunisations at the appropriate chronological age regardless of prematurity, but they comment that there is no research to justify this. 3 There are good theoretical grounds for supposing that preterm infants will be able to mount immune responses comparable with those born at full term. Antibody production increases with age, but this is related to duration of exposure to the antigen after birth rather than postconceptional age.4 Studies on cell mediated immunity suggest that preterm infants behave similarly to those born at full term.6
The small amount of work that has been done on routine immunisation of preterm infants supports this view. Smolen et al looked at antibody responses to polio virus vaccine after two months and four months in 37 preterm infants; they had similar levels of antibody to those born at full term.7 Bernbaum et al studied 25 infants from 28 to 34 weeks' gestation given triple vaccine (diphtheria, tetanus, and pertussis) at the ages of 2, 4, and 6 months.8 After the first injection fewer preterm infants had satisfactory antibody concentrations, but by the second and third injections there were no significant differences when compared with those born at full term.
In Nottingham the local recommendation is for preterm infants to start the immunisation programme three months from birth, whatever the period of gestation, or as soon as possible after this. We have followed up Pertussis antibodies These were estimated by an ELISA similar to that described above but using the supernatant from centrifuged sonicated cells of Bordetella pertussis strain W28 at a concentration of 8 ng protein/ml as antigen. The human reference was a serum pool from normal children vaccinated who had been vaccinated against diphtheria, tetanus, and pertussis, which had a nominal concentration of 100 pertussis antibody units/ml. Pertussis antibodies were detected using alkaline phosphatase conjugated antihuman polyvalent immunoglobulins (raised against a, y, and ,u chains). Results Fifty preterm infants completed the study (22 from 32-36 weeks' gestation, 19 from 28-31 weeks' gestation, and nine either 26 or 27 weeks' gestation). Twenty one control samples were analysed.
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Many of the infants were able to start their immunisations by 12-13 weeks of age (fig 1) . There was an inevitable delay with some of the very sick infants. The longest delays in starting immunisation were for social reasons-for instance, difficulty in getting the child to the clinic. One child was delayed while uncertainty about possible fits was being resolved. Five children had their first dose in the neonatal unit, and two of these had all their immunisations in hospital. One child of 33 weeks' gestation, who was immunised at the age of 16 weeks, was described as 'jittery' after the first triple dose, and had pertussis omitted from the second and third doses. No other reactions were reported other than mild fever, irritability, and redness at the injection site.
There were no neonatal contraindications to pertussis vaccine in any of the children despite some having had complicated neonatal courses. All the children started immunisation with the triple antigen. Two children were diagnosed as having cerebral palsy (one probably spastic quadriplegia, one mild hemiplegia). Both these children were born at 27 weeks' gestation and it was thought that the benefit from pertussis immunisation outweighed any possible risk.
Two children (of 27 and 31 weeks' gestation, respectively) had had admissions for asthma in the first year of life. One child (of 26 weeks' gestation) had persistent failure to thrive and feeding difficulties. One child (of 29 weeks' gestation) had necrotising enterocolitis necessitating resection of bowel. One child (of 26 weeks' gestation) had a tracheooesophageal fistula and a hand anomaly. 25 
Routine immunisation ofpreterm infants 1441
Forty two of the children had blood samples taken for antibody measurements 8-12 weeks after the third immunisation. One child had the sample taken at one week, seven between 13-17 weeks, and one was 21 weeks after diphtheria, tetanus, and polio and five weeks after the pertussis (the third pertussis injection was delayed because of a question about contraindications). The immunological responses of all children were satisfactory to all antigens compared with the controls (table, fig 2) . There was no relation between response and gestational age (individual values for pertussis are shown in fig 3) Individual health staff within the community only rarely have to advise about immature infants. This may lead to a tendency to 'play safe' and postpone immunisation or even omit the pertussis immunisation altogether. A clear recommendation from the neonatal unit on neonatal contraindications to pertussis and the lack of them, and advice on the age at which to start, should help to overcome this. 
